Get updates to this list
You’re signing up to all partnering opportunity alerts for:
Please check your inbox
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to complete your subscription
You've successfully created a subscription
The search results below each have a summary which you may find useful
in determining if the opportunity is what you’re looking for.
The French pharmaceutical company is developing a new oral small molecule targeting the lysosomal compartment of cancer cells, including cancer stem cells.
In vitro data confirmed the anti-cancer agent action on many tumor types (colon carcinoma,... more
A French clinical research team has developped an innovative paediatric treatment for autistic disorders coming from a specific enzym deficiency. The team is represented by a Technology Transfer Office (TTO) which... more
A French clinical research team has developed an innovative treatment for paediatric epileptic seizures coming from a vitamin-sensitive effect. This research team is represented by a Technology Transfer Office... more
Ukrainian research and development clinical institution was established in 1920. Now it is the leading organization in the country which conducts cancer research on the basic, translational and clinical... more
The French company is a pre-clinical biotech company with a strong expertise in the fild of monogenetic disorders designing and developing miniaturised and automated in vitro cellular and phenotypic assays based... more
24/7 that allow having a clear image of the exact ongoing condition. Although some systems are available for use in clinical settings, there is not yet an option for parents to monitor signs reliably at home.... more
Background: The company was founded some years ago as a spin-off from a Southern German university. The company offers a solution for structured medical reporting and clinical guidance. The first platform was launched... more
of cancer and other complex diseases with an important genetic background. However, the in vivo delivery of oligonucleotides (OGN) has precluded the clinical use of gene-based therapies mainly due to its vulnerability... more
) orphan disease space—the company’s therapeutic focus.
The company’s pipeline consists of clinical-stage assets for Huntington’s disease and Adrenoleukodystrophy, as well as preclinical-stage assets for Adrenomyeloneuropathy,... more
Wnt signalling is implicated, such as stonach, liver and pancreatic cancer. Testing on this molecule shows that it displays anti-proliferative activity in pre-clinical in vivo models, has a favourable pharmacokinetic... more
oral and ocular application. They published over a hundred articles in high-impact scientific journals.
Partners are sought to participate with the finalisation of the pre-clinical and/or clinical... more
The Italian company offers a full range of histology and cytology tests for oncology. Stemming from the clinical experience the molecular tests are based on the choice of the most important genes involved in the... more
quality assurance laboratories including cell biology and molecular biology laboratories. Company’s customers include hospitals, biotech and pharmaceutical companies conducting cell therapy-based clinical trials.
early stage melanoma at risk of unexpected progression after surgical treatment or earlier in treatment.
Biotechnology and/or pharmaceutical company or SMEs are sought for license or financial agreement.
The area of activity of the partner... more
planning a pregnancy. Therefore, the risk of having a child suffering from a genetic condition is largely eliminated.
The SME is looking for partners to help them pioneer the technology in their clinical practice.... more
performing pre-clinical studies where both acute toxicity and efficacy tests were cleared confirming therefore the compound therapeutic effects that are at least twice more efficient than the drugs actually on... more
numerous caspase-1 inhibitors have been synthesized, no inhibitor has passed the clinical trial, probably because of the covalent mechanism of action and the consequent unwanted off-target interactions.
The research... more
therapeutic interventions with the latest digital solutions in a secure, user friendly web-based environment. It uses a blended approach where therapeutic interventions are supported by online tools and clinical... more
indication. Until now, only a few materials are under research investigation. Moreover, such results haven't reached the clinical milestone yet because of an obvious major issue : it is strongly difficult to set... more
pressing need for innovative treatments.
Based on preclinical studies on vascular smooth muscle cells, isolated organ studies and animal models, the low molecular weight clinical candidate of the Swiss biotech... more